| 于海宁,钱 诚.唑来膦酸在乳腺癌中抗肿瘤作用的研究进展[J].中国肿瘤,2017,26(6):460-464. |
| 唑来膦酸在乳腺癌中抗肿瘤作用的研究进展 |
| Research Progress in Antitumor Effects of Zoledronic Acid in Breast Cancer |
| 投稿时间：2016-09-12 |
| DOI：10.11735/j.issn.1004-0242.2017.06.A009 |
|
 |
| 中文关键词: 乳腺肿瘤 唑来膦酸 抗肿瘤药物 |
| 英文关键词:breast neoplasms zoledronic acid antitumor drug |
| 基金项目:黑龙江省教育厅海外学人科研资助项目（1253HQ002） |
|
| 摘要点击次数: 1635 |
| 全文下载次数: 592 |
| 中文摘要: |
| 摘 要：唑来膦酸（ZOL）是第三代双膦酸盐类药物的典型代表，在已上市的双膦酸盐类药物中应用最广泛、综合疗效最好，现已作为乳腺癌骨转移的常规治疗药物。多项临床前研究及临床研究已证实，唑来膦酸对肿瘤细胞有直接或间接的抑制作用，联合其他辅助治疗（化疗和内分泌治疗）可发挥协同作用，对改善乳腺癌患者术后生存、抑制复发及转移具有重要作用，本文就上述研究进展作一综述。 |
| 英文摘要: |
| Abstract：Zoledronic acid(ZOL) is the third generation of bisphosphonates，it is used as the standard therapy for bone metastases in breast cancer and shows excellent therapeutic effect. Several preclinical and clinical studies indicate that ZOL can inhibit tumor cells directly or indirectly，exert synergistic effect with chemotherapy and endocrine therapy. ZOL can significantly reduce cancer recurrence and metastasis，and improve postoperative survival of breast cancer patients. This article reviews the research progress on the antitumor of zoledronic acid in breast cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |